Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of hepatorenal syndrome. In cases where terlipre...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Gastroenterology Insights |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7422/14/4/31 |
| _version_ | 1797380980744388608 |
|---|---|
| author | Ahlam Ayyad Rami A. Al-Horani |
| author_facet | Ahlam Ayyad Rami A. Al-Horani |
| author_sort | Ahlam Ayyad |
| collection | DOAJ |
| description | Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of hepatorenal syndrome. In cases where terlipressin therapy is accessible, the initial approach involves administering terlipressin alongside albumin. Terlipressin, a synthetic analog of vasopressin, boasts double the preference for vasopressin V1 receptors compared to V2 receptors. The FDA granted approval to terlipressin in September 2022, demonstrating its intrinsic activity, although a significant portion of its function arises from its transformation into lysine vasopressin. This article provides a comprehensive examination of terlipressin’s various pharmacodynamic and pharmacokinetic facets, as well as its clinical utility, aiming to keep the scientific community well informed about its safe and efficient utilization. |
| first_indexed | 2024-03-08T20:44:48Z |
| format | Article |
| id | doaj.art-70a2cf6f5c1d42e6b32a5cda882a0bd8 |
| institution | Directory Open Access Journal |
| issn | 2036-7414 2036-7422 |
| language | English |
| last_indexed | 2024-03-08T20:44:48Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gastroenterology Insights |
| spelling | doaj.art-70a2cf6f5c1d42e6b32a5cda882a0bd82023-12-22T14:10:29ZengMDPI AGGastroenterology Insights2036-74142036-74222023-09-0114442043010.3390/gastroent14040031Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug ProfileAhlam Ayyad0Rami A. Al-Horani1Division of Clinical and Administrative Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USADivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USAHepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of hepatorenal syndrome. In cases where terlipressin therapy is accessible, the initial approach involves administering terlipressin alongside albumin. Terlipressin, a synthetic analog of vasopressin, boasts double the preference for vasopressin V1 receptors compared to V2 receptors. The FDA granted approval to terlipressin in September 2022, demonstrating its intrinsic activity, although a significant portion of its function arises from its transformation into lysine vasopressin. This article provides a comprehensive examination of terlipressin’s various pharmacodynamic and pharmacokinetic facets, as well as its clinical utility, aiming to keep the scientific community well informed about its safe and efficient utilization.https://www.mdpi.com/2036-7422/14/4/31hepatorenal syndromeacute kidney injuryterlipressinvasopressin analogue |
| spellingShingle | Ahlam Ayyad Rami A. Al-Horani Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile Gastroenterology Insights hepatorenal syndrome acute kidney injury terlipressin vasopressin analogue |
| title | Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile |
| title_full | Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile |
| title_fullStr | Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile |
| title_full_unstemmed | Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile |
| title_short | Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile |
| title_sort | terlipressin for the prevention and treatment of renal decline in hepatorenal syndrome a drug profile |
| topic | hepatorenal syndrome acute kidney injury terlipressin vasopressin analogue |
| url | https://www.mdpi.com/2036-7422/14/4/31 |
| work_keys_str_mv | AT ahlamayyad terlipressinforthepreventionandtreatmentofrenaldeclineinhepatorenalsyndromeadrugprofile AT ramiaalhorani terlipressinforthepreventionandtreatmentofrenaldeclineinhepatorenalsyndromeadrugprofile |